|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
|
WO2010021381A1
(ja)
|
2008-08-22 |
2010-02-25 |
武田薬品工業株式会社 |
縮合複素環誘導体およびその用途
|
|
US8846935B2
(en)
|
2010-05-07 |
2014-09-30 |
Glaxosmithkline Llc |
Indazoles
|
|
MX2012012966A
(es)
|
2010-05-07 |
2013-01-22 |
Glaxosmithkline Llc |
Indoles.
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
WO2012068589A2
(en)
|
2010-11-19 |
2012-05-24 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
AU2011341441A1
(en)
|
2010-12-03 |
2013-06-20 |
Epizyme, Inc. |
Modulators of histone methyltransferase, and methods of use thereof
|
|
WO2012118812A2
(en)
|
2011-02-28 |
2012-09-07 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
TW201733984A
(zh)
|
2011-04-13 |
2017-10-01 |
雅酶股份有限公司 |
經取代之苯化合物
|
|
WO2012154760A1
(en)
|
2011-05-10 |
2012-11-15 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as sodium channel modulators
|
|
US9730925B2
(en)
|
2011-09-30 |
2017-08-15 |
Glaxomithkline Llc |
Methods of treating cancer
|
|
CA2853501A1
(en)
|
2011-10-27 |
2013-05-02 |
Memorial Sloan-Kettering Cancer Center |
Methyltransferase inhibitors for treating cancer
|
|
WO2013075084A1
(en)
|
2011-11-18 |
2013-05-23 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9206128B2
(en)
|
2011-11-18 |
2015-12-08 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9085583B2
(en)
|
2012-02-10 |
2015-07-21 |
Constellation—Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
EP2836216B1
(en)
|
2012-04-13 |
2022-06-08 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
US9562041B2
(en)
|
2012-05-16 |
2017-02-07 |
Glaxosmithkline Llc |
Enhancer of zeste homolog 2 inhibitors
|
|
US9105490B2
(en)
|
2012-09-27 |
2015-08-11 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Contact structure of semiconductor device
|
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
|
BR112015008480A2
(pt)
|
2012-10-15 |
2017-07-04 |
Epizyme Inc |
compostos de benzeno substituído
|
|
KR20190105669A
(ko)
|
2012-10-15 |
2019-09-17 |
에피자임, 인코포레이티드 |
암을 치료하는 방법
|
|
RU2015127822A
(ru)
|
2012-12-13 |
2017-01-16 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Ингибиторы энхансера гомолога 2 белка zeste
|
|
CA2894216A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
1,4-pyridone compounds
|
|
CA2894222A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
1,4-pyridone bicyclic heteroaryl compounds
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
PL2953941T3
(pl)
|
2013-02-11 |
2017-11-30 |
Constellation Pharmaceuticals, Inc. |
Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
|
|
US20160031907A1
(en)
|
2013-03-15 |
2016-02-04 |
Epizyme, Inc. |
Substituted Benzene Compounds
|
|
US9745305B2
(en)
|
2013-03-15 |
2017-08-29 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9243001B2
(en)
|
2013-03-15 |
2016-01-26 |
Epizyme, Inc. |
Substituted benzene compounds
|
|
US9045477B2
(en)
|
2013-03-15 |
2015-06-02 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
EP2970306A4
(en)
|
2013-03-15 |
2016-08-03 |
Epizyme Inc |
SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
|
|
HK1214815A1
(zh)
|
2013-04-30 |
2016-08-05 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Zeste增强子同源物2的抑制剂
|
|
CA2914414A1
(en)
|
2013-06-06 |
2014-12-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
CA2917463A1
(en)
|
2013-07-10 |
2015-01-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
EP3022184B1
(en)
|
2013-07-19 |
2017-09-27 |
Epizyme, Inc. |
Substituted benzene compounds
|
|
US9624205B2
(en)
|
2013-07-19 |
2017-04-18 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
US9969716B2
(en)
|
2013-08-15 |
2018-05-15 |
Constellation Pharmaceuticals, Inc. |
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9738630B2
(en)
|
2013-11-19 |
2017-08-22 |
Bristol-Myers Squibb Company |
Inhibitors of lysine methyl transferase
|
|
WO2015077194A1
(en)
|
2013-11-22 |
2015-05-28 |
Bristol-Myers Squibb Company |
Inhibitors of lysine methyl transferase
|
|
US20160361309A1
(en)
|
2014-02-26 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
AU2015225775B2
(en)
|
2014-03-07 |
2017-06-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of Zeste Homolog 2 inhibitors
|
|
PL3121175T3
(pl)
|
2014-03-17 |
2020-06-01 |
Daiichi Sankyo Company, Limited |
Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2
|
|
AP2016009605A0
(en)
|
2014-06-17 |
2016-12-31 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
|
MA40848A
(fr)
|
2014-10-28 |
2021-05-05 |
Glaxosmithkline Ip No 2 Ltd |
Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
|
|
CA2964629A1
(en)
|
2014-11-06 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
BR112017009440A2
(pt)
|
2014-11-06 |
2017-12-19 |
Dana Farber Cancer Inst Inc |
uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
|
|
TW201636344A
(zh)
|
2014-12-05 |
2016-10-16 |
美國禮來大藥廠 |
Ｅｚｈ２抑制劑
|
|
WO2016102493A1
(en)
|
2014-12-22 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
Imidazopyridine ezh2 inhibitors
|
|
IL236420A
(en)
|
2014-12-23 |
2016-06-30 |
Ron Schneider |
Methods and systems for producing an enlarged 3D image
|
|
MX375970B
(es)
|
2014-12-23 |
2025-03-06 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos.
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US20180037568A1
(en)
|
2015-02-13 |
2018-02-08 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
TW201718598A
(zh)
|
2015-08-27 |
2017-06-01 |
美國禮來大藥廠 |
Ｅｚｈ２抑制劑
|
|
SI3378859T1
(sl)
|
2015-11-19 |
2020-03-31 |
Jiangsu Hengrui Medicine Co., Ltd., |
Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini
|
|
EP3386513A2
(en)
|
2015-12-07 |
2018-10-17 |
Epizyme Inc |
Inhibitors of ezh2 and methods of use thereof
|
|
WO2017174023A1
(zh)
|
2016-04-08 |
2017-10-12 |
南京明德新药研发股份有限公司 |
作为ezh2抑制剂的联苯化合物
|
|
WO2017184999A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
WO2017191545A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
US9957274B2
(en)
|
2016-05-06 |
2018-05-01 |
Abbvie Inc. |
Indane inhibitors of EED and methods of their use
|
|
US11786533B2
(en)
|
2016-06-01 |
2023-10-17 |
Epizyme, Inc. |
Use of EZH2 inhibitors for treating cancer
|
|
US11147819B2
(en)
|
2016-06-17 |
2021-10-19 |
Epizyme, Inc. |
EZH2 inhibitors for treating cancer
|
|
JP2019524872A
(ja)
*
|
2016-06-20 |
2019-09-05 |
ノバルティス アーゲー |
癌の治療に有用なイミダゾピリミジン化合物
|
|
US10689378B2
(en)
|
2016-06-20 |
2020-06-23 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
JP7042812B2
(ja)
|
2016-06-20 |
2022-03-28 |
ノバルティス アーゲー |
トリアゾロピリミジン化合物の結晶形態
|
|
US10266542B2
(en)
|
2017-03-15 |
2019-04-23 |
Mirati Therapeutics, Inc. |
EZH2 inhibitors
|
|
WO2019062435A1
(zh)
|
2017-09-28 |
2019-04-04 |
中国科学院上海药物研究所 |
三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
|
|
CN109942556A
(zh)
|
2017-12-21 |
2019-06-28 |
上海青煜医药科技有限公司 |
嘧啶酮化合物及其应用
|
|
DK3746446T3
(da)
|
2018-01-31 |
2022-06-27 |
Mirati Therapeutics Inc |
PRC2-inhibitorer
|
|
CN110156787B
(zh)
|
2018-02-13 |
2021-11-02 |
中国科学院上海药物研究所 |
一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
|
|
CN110563722A
(zh)
|
2018-06-06 |
2019-12-13 |
上海青煜医药科技有限公司 |
吡啶或哒嗪并环化合物及其应用
|
|
US12421228B2
(en)
|
2019-04-22 |
2025-09-23 |
Mirati Therapeutics, Inc. |
Naphthyridine derivatives as PRC2 inhibitors
|
|
CN114269748A
(zh)
|
2019-06-05 |
2022-04-01 |
米拉蒂医疗股份有限公司 |
作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
|